Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof

US10501510B2 · kind B2 · utility

Assignee

• Pieris Pharmaceuticals GmbH · DE

Inventors

• Christine Rothe · Freising, DE
• Andrea Allersdorfer · Wolnzach, DE
• Alexander Wiedenmann · Ulm, DE
• Rachida Siham Bel Aiba · Munich, DE
• Shane Olwill · Freising, DE
• Timo Eichner · Freising, DE

Key dates

• Filing date: Jul 15, 2016
• Grant date: Dec 10, 2019
• Expiry date: Jul 15, 2036

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/70539
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.